In comparison to our study, they found a significant enrichment only in KRAS mutations in ES-NSCLC and in ALK gene fusions in advanced NSCLC, but they reported a lower prevalence of MET exon14 skipping alterations (2.1%) and a higher prevalence of BRAF p.(V600E) (2.3%) in advanced tumors [24]. This evidence concerns the gene ALK and non-small cell lung carcinoma.